Species to EP 0780386.

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1611hxl
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 6	Oct 22	Over 1 million reactions added to CASREACT
NEWS 7	Oct 22	DGENE GETSIM has been improved
NEWS 8	Oct 29	AAASD no longer available
NEWS 9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 11	Nov 29	COPPERLIT now available on STN
NEWS 12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 13	Nov 30	Files VETU and VETB to have open access
NEWS 14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 15	Dec 10	DGENE BLAST Homology Search
NEWS 16	Dec 17	WELDASEARCH now available on STN
NEWS 17	Dec 17	STANDARDS now available on STN
NEWS 18	Dec 17	New fields for DPCI
NEWS 19	Dec 19	CAS Roles modified
NEWS 20	Dec 19	1907-1946 data and page images added to CA and CAplus
NEWS 21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 22	Jan 25	Searching with the P indicator for Preparations
NEWS 23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 24	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Hong Liu

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:53:33 ON 07 FEB 2002

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'CAPLUS' ENTERED AT 10:54:12 ON 07 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Feb 2002 VOL 136 ISS 6
FILE LAST UPDATED: 6 Feb 2002 (20020206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

=> s780386/pn
S780386 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 780386/pn
L1 0 780386/PN

```
=> s ep780386/pn
L2            1 EP780386/PN

=> select l2 rn 1-
E1 THROUGH E174 ASSIGNED

=> fil reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               4.01       4.16

FILE 'REGISTRY' ENTERED AT 10:55:16 ON 07 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    5 FEB 2002  HIGHEST RN 389795-01-1
DICTIONARY FILE UPDATES:   5 FEB 2002  HIGHEST RN 389795-01-1

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between
12/27/01 and 1/23/02.  Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved.  Also, note that searches
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files
incorporating CAS Registry Numbers with the P indicator between 12/27/01
and 1/23/02, are encouraged to re-run these strategies.  Contact the
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,
worldwide, or send an e-mail to help@cas.org for further assistance or to
receive a credit for any duplicate searches.

=> s e1-e174
             1 100-39-0/BI
               (100-39-0/RN)
             1 101-55-3/BI
               (101-55-3/RN)
             1 105-53-3/BI
               (105-53-3/RN)
             1 111-44-4/BI
```

(111-44-4/RN)
1 130312-01-5/BI
(130312-01-5/RN)
1 13511-38-1/BI
(13511-38-1/RN)
1 141907-41-7/BI
(141907-41-7/RN)
1 142851-03-4/BI
(142851-03-4/RN)
1 19099-93-5/BI
(19099-93-5/RN)
1 193021-77-1/BI
(193021-77-1/RN)
1 193021-78-2/BI
(193021-78-2/RN)
1 193021-79-3/BI
(193021-79-3/RN)
1 193021-80-6/BI
(193021-80-6/RN)
1 193021-81-7/BI
(193021-81-7/RN)
1 193021-82-8/BI
(193021-82-8/RN)
1 193021-83-9/BI
(193021-83-9/RN)
1 193021-84-0/BI
(193021-84-0/RN)
1 193021-85-1/BI
(193021-85-1/RN)
1 193021-86-2/BI
(193021-86-2/RN)
1 193021-87-3/BI
(193021-87-3/RN)
1 193021-88-4/BI
(193021-88-4/RN)
1 193021-89-5/BI
(193021-89-5/RN)
1 193021-90-8/BI
(193021-90-8/RN)
1 193021-91-9/BI
(193021-91-9/RN)
1 193021-92-0/BI
(193021-92-0/RN)
1 193021-93-1/BI
(193021-93-1/RN)
1 193021-94-2/BI
(193021-94-2/RN)
1 193021-95-3/BI
(193021-95-3/RN)
1 193021-96-4/BI
(193021-96-4/RN)
1 193021-97-5/BI
(193021-97-5/RN)
1 193021-98-6/BI

(193021-98-6/RN)
1 193021-99-7/BI
(193021-99-7/RN)
1 193022-00-3/BI
(193022-00-3/RN)
1 193022-01-4/BI
(193022-01-4/RN)
1 193022-02-5/BI
(193022-02-5/RN)
1 193022-03-6/BI
(193022-03-6/RN)
1 193022-04-7/BI
(193022-04-7/RN)
1 193022-05-8/BI
(193022-05-8/RN)
1 193022-06-9/BI
(193022-06-9/RN)
1 193022-07-0/BI
(193022-07-0/RN)
1 193022-08-1/BI
(193022-08-1/RN)
1 193022-09-2/BI
(193022-09-2/RN)
1 193022-10-5/BI
(193022-10-5/RN)
1 193022-11-6/BI
(193022-11-6/RN)
1 193022-12-7/BI
(193022-12-7/RN)
1 193022-13-8/BI
(193022-13-8/RN)
1 193022-14-9/BI
(193022-14-9/RN)
1 193022-15-0/BI
(193022-15-0/RN)
1 193022-16-1/BI
(193022-16-1/RN)
1 193022-17-2/BI
(193022-17-2/RN)
1 193022-18-3/BI
(193022-18-3/RN)
1 193022-19-4/BI
(193022-19-4/RN)
1 193022-20-7/BI
(193022-20-7/RN)
1 193022-21-8/BI
(193022-21-8/RN)
1 193022-22-9/BI
(193022-22-9/RN)
1 193022-23-0/BI
(193022-23-0/RN)
1 193022-24-1/BI
(193022-24-1/RN)
1 193022-25-2/BI

(193022-25-2/RN)
1 193022-26-3/BI
(193022-26-3/RN)
1 193022-27-4/BI
(193022-27-4/RN)
1 193022-28-5/BI
(193022-28-5/RN)
1 193022-29-6/BI
(193022-29-6/RN)
1 193022-30-9/BI
(193022-30-9/RN)
1 193022-31-0/BI
(193022-31-0/RN)
1 193022-32-1/BI
(193022-32-1/RN)
1 193022-33-2/BI
(193022-33-2/RN)
1 193022-34-3/BI
(193022-34-3/RN)
1 193022-35-4/BI
(193022-35-4/RN)
1 193022-36-5/BI
(193022-36-5/RN)
1 193022-37-6/BI
(193022-37-6/RN)
1 193022-38-7/BI
(193022-38-7/RN)
1 193022-39-8/BI
(193022-39-8/RN)
1 193022-40-1/BI
(193022-40-1/RN)
1 193022-41-2/BI
(193022-41-2/RN)
1 193022-42-3/BI
(193022-42-3/RN)
1 193022-43-4/BI
(193022-43-4/RN)
1 193022-44-5/BI
(193022-44-5/RN)
1 193022-45-6/BI
(193022-45-6/RN)
1 193022-46-7/BI
(193022-46-7/RN)
1 193022-47-8/BI
(193022-47-8/RN)
1 193022-48-9/BI
(193022-48-9/RN)
1 193022-49-0/BI
(193022-49-0/RN)
1 193022-50-3/BI
(193022-50-3/RN)
1 193022-51-4/BI
(193022-51-4/RN)
1 193022-52-5/BI

(193022-52-5/RN)
1 193022-53-6/BI
(193022-53-6/RN)
1 193022-54-7/BI
(193022-54-7/RN)
1 193022-55-8/BI
(193022-55-8/RN)
1 193022-56-9/BI
(193022-56-9/RN)
1 193022-57-0/BI
(193022-57-0/RN)
1 193022-58-1/BI
(193022-58-1/RN)
1 193022-59-2/BI
(193022-59-2/RN)
1 193022-60-5/BI
(193022-60-5/RN)
1 193022-61-6/BI
(193022-61-6/RN)
1 193022-62-7/BI
(193022-62-7/RN)
1 193022-63-8/BI
(193022-63-8/RN)
1 193022-64-9/BI
(193022-64-9/RN)
1 193022-65-0/BI
(193022-65-0/RN)
1 193022-66-1/BI
(193022-66-1/RN)
1 193022-67-2/BI
(193022-67-2/RN)
1 193022-68-3/BI
(193022-68-3/RN)
1 193022-69-4/BI
(193022-69-4/RN)
1 193022-70-7/BI
(193022-70-7/RN)
1 193022-71-8/BI
(193022-71-8/RN)
1 193022-72-9/BI
(193022-72-9/RN)
1 193022-73-0/BI
(193022-73-0/RN)
1 193022-74-1/BI
(193022-74-1/RN)
1 193022-75-2/BI
(193022-75-2/RN)
1 193022-76-3/BI
(193022-76-3/RN)
1 193022-77-4/BI
(193022-77-4/RN)
1 193022-78-5/BI
(193022-78-5/RN)
1 193022-79-6/BI

(193022-79-6/RN)
1 193022-80-9/BI
(193022-80-9/RN)
1 193022-81-0/BI
(193022-81-0/RN)
1 193022-82-1/BI
(193022-82-1/RN)
1 193022-83-2/BI
(193022-83-2/RN)
1 193022-84-3/BI
(193022-84-3/RN)
1 193022-85-4/BI
(193022-85-4/RN)
1 193022-86-5/BI
(193022-86-5/RN)
1 193022-87-6/BI
(193022-87-6/RN)
1 193022-88-7/BI
(193022-88-7/RN)
1 193022-89-8/BI
(193022-89-8/RN)
1 193022-90-1/BI
(193022-90-1/RN)
1 193022-91-2/BI
(193022-91-2/RN)
1 193022-92-3/BI
(193022-92-3/RN)
1 193022-93-4/BI
(193022-93-4/RN)
1 193022-94-5/BI
(193022-94-5/RN)
1 193022-95-6/BI
(193022-95-6/RN)
1 193022-96-7/BI
(193022-96-7/RN)
1 193022-97-8/BI
(193022-97-8/RN)
1 193022-98-9/BI
(193022-98-9/RN)
1 193022-99-0/BI
(193022-99-0/RN)
1 193023-00-6/BI
(193023-00-6/RN)
1 193023-01-7/BI
(193023-01-7/RN)
1 193023-02-8/BI
(193023-02-8/RN)
1 193023-03-9/BI
(193023-03-9/RN)
1 193023-04-0/BI
(193023-04-0/RN)
1 193023-05-1/BI
(193023-05-1/RN)
1 193023-06-2/BI

(193023-06-2/RN)
1 193023-07-3/BI
(193023-07-3/RN)
1 193023-08-4/BI
(193023-08-4/RN)
1 193023-09-5/BI
(193023-09-5/RN)
1 193023-10-8/BI
(193023-10-8/RN)
1 193023-11-9/BI
(193023-11-9/RN)
1 193023-12-0/BI
(193023-12-0/RN)
1 193023-13-1/BI
(193023-13-1/RN)
1 193023-14-2/BI
(193023-14-2/RN)
1 193023-15-3/BI
(193023-15-3/RN)
1 193023-16-4/BI
(193023-16-4/RN)
1 193023-17-5/BI
(193023-17-5/RN)
1 193023-18-6/BI
(193023-18-6/RN)
1 193023-19-7/BI
(193023-19-7/RN)
1 20260-53-1/BI
(20260-53-1/RN)
1 26054-60-4/BI
(26054-60-4/RN)
1 29943-42-8/BI
(29943-42-8/RN)
1 38778-05-1/BI
(38778-05-1/RN)
1 39684-28-1/BI
(39684-28-1/RN)
1 40113-03-9/BI
(40113-03-9/RN)
1 501-53-1/BI
(501-53-1/RN)
1 51289-12-4/BI
(51289-12-4/RN)
1 5337-03-1/BI
(5337-03-1/RN)
1 5382-16-1/BI
(5382-16-1/RN)
1 5382-77-4/BI
(5382-77-4/RN)
1 59621-76-0/BI
(59621-76-0/RN)
1 6165-68-0/BI
(6165-68-0/RN)
1 6165-69-1/BI

(6165-69-1/RN)
1 637-69-4/BI
(637-69-4/RN)
1 67-64-1/BI
(67-64-1/RN)
1 6959-48-4/BI
(6959-48-4/RN)
1 7051-34-5/BI
(7051-34-5/RN)
1 84358-13-4/BI
(84358-13-4/RN)
1 95798-23-5/BI
(95798-23-5/RN)
1 96835-17-5/BI
(96835-17-5/RN)
1 98-80-6/BI
(98-80-6/RN)
L3 174 (100-39-0/BI OR 101-55-3/BI OR 105-53-3/BI OR 111-44-4/BI OR 130312-01-5/BI OR 13511-38-1/BI OR 141907-41-7/BI OR 142851-03-4
/BI OR 19099-93-5/BI OR 193021-77-1/BI OR 193021-78-2/BI OR 193021-79-3/BI OR 193021-80-6/BI OR 193021-81-7/BI OR 193021-82-
8/BI OR 193021-83-9/BI OR 193021-84-0/BI OR 193021-85-1/BI OR 193021-86-2/BI OR 193021-87-3/BI OR 193021-88-4/BI OR 193021-89-
5/BI OR 193021-90-8/BI OR 193021-91-9/BI OR 193021-92-0/BI OR 193021-93-1/BI OR 193021-94-2/BI OR 193021-95-3/BI OR 193021-96-
4/BI OR 193021-97-5/BI OR 193021-98-6/BI OR 193021-99-7/BI OR 193022-00-3/BI OR 193022-01-4/BI OR 193022-02-5/BI OR 193022-03-
6/BI OR 193022-04-7/BI OR 193022-05-8/BI OR 193022-06-9/BI OR 193022-07-0/BI OR 193022-08-1/BI OR 193022-09-2/BI OR 193022-10-
5/BI OR 193022-11-6/BI OR 193022-12-7/BI OR 193022-13-8/BI OR 193022-14-9/BI OR 193022-15-0/BI OR 193022-16-1/BI OR 193022-17-
2/BI OR 193022-18-3/BI OR 193022-19-4/BI OR 193022-20-7/BI OR 193022-21-8/BI OR 193022-22-9/BI OR 193022-23-0/

=> d scan

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-[(5-chloro-2-pyridinyl)oxy]- (9CI)
MF C11 H8 Cl N O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):173

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide,
N-(1,1-dimethylethoxy)-1-(methylsulfonyl)-4-[[(4-
phenoxyphenyl)sulfonyl]methyl]- (9CI)
MF C24 H32 N2 O7 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Pentanamide, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI)
MF C13 H19 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetamide, N-hydroxy-1-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C19 H21 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-hydroxy-, phenylmethyl ester (9CI)
MF C13 H17 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-[[(1,1-dimethylethoxy)amino]carbonyl]-4-[[(4-phenoxyphenyl)thio]methyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H38 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl
]tetrahydro-3-(phenylmethyl)-, methyl ester (9CI)
MF C27 H27 Cl O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanoic acid, .beta.-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI)
MF C22 H20 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide, 4-[[4-(cyclohexyloxy)phenyl]sulfonyl]tetrahydro-N-
hydroxy- (9CI)
MF C19 H27 N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 3-[[4-(4-chlorophenoxy)phenyl]thio]-N-hydroxy-2,2-dimethyl- (9CI)
MF C17 H18 Cl N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopropane, (bromomethyl)- (7CI, 8CI, 9CI)
MF C4 H7 Br



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-(iodomethyl)-, ethyl ester (9CI)
MF C9 H15 I O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C23 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentanecarboxamide, N-hydroxy-2-[(4-methoxyphenyl)sulfonyl]-, trans- (9CI)
MF C13 H17 N O5 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-[4-(2-thienyl)phenoxy]phenyl]sulfonyl]methyl]- (9CI)

MF C23 H23 N O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-bromophenoxy)phenyl]thio]methyl]tetr
ahydro- (9CI)
MF C19 H19 Br O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzene, (bromomethyl)- (9CI)
MF C7 H7 Br
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Propanamide, 2-(dimethylamino)-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, (R)- (9CI)
MF C17 H20 N2 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-(1,1-dimethylethoxy)-1-(1-methylethyl)-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C26 H36 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C22 H21 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetamide, N-hydroxy-1-[(4-phenoxyphenyl)thio]- (9CI)
MF C19 H21 N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Hydroxylamine, O-(1,1-dimethylethyl)-, hydrochloride (9CI)
MF C4 H11 N O . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanoic acid, .beta.-[[4-(2-phenylethenyl)phenyl]sulfonyl]- (9CI)
MF C24 H22 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Carbamic acid, [2-(hydroxyamino)-2-oxo-1-[[(4-phenoxyphenyl)sulfonyl]methyl]ethyl]-, phenylmethyl ester, (R)- (9CI)
MF C23 H22 N2 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-(methylsulfonyl)-, monohydrochloride (9CI)
MF C20 H23 Cl N2 O7 S2 . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-2-oxoethyl]-4-[(4-phenoxyphenyl)sulfonyl]-, phenylmethyl ester (9CI)
MF C27 H28 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetic acid, 4-[[4-(4-chlorophenoxy)phenyl]thio]tetrahydro-
(9CI)
MF C19 H19 Cl O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinol (6CI, 7CI, 8CI, 9CI)
MF C5 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Piperidinedicarboxylic acid, 4-(hydroxymethyl)-,
1-(1,1-dimethylethyl)
4-ethyl ester (9CI)

MF C14 H25 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C22 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclohexaneacetamide, N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-4-methyl- (9CI)
MF C16 H23 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tet
rahydro-N-hydroxy-3-(phenylmethyl)- (9CI)
MF C26 H26 Cl N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Acetic acid, (tetrahydro-4H-pyran-4-ylidene)- (9CI)
MF C7 H10 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanoic acid, .beta.-[(4-bromophenyl)thio]- (9CI)
MF C16 H15 Br O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-(dimethylamino)-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride, (R)- (9CI)
MF C17 H20 N2 O5 S . Cl H

Absolute stereochemistry.



L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-[[[4-[4-(2-thienyl)phenoxy]phenyl]sulfonyl]methyl]- (9CI)
MF C23 H22 O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenepropanamide,
N-hydroxy-.alpha.-[[(4-methoxyphenyl)sulfonyl]methyl]-
(9CI)
MF C17 H19 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide, N-(1,1-dimethylethoxy)tetrahydro-4-[(4-
phenoxyphenyl)thio]- (9CI)
MF C23 H29 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-oxo-, phenylmethyl ester (9CI)
MF C13 H15 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, 4-(chloromethyl)tetrahydro-, ethyl ester (9CI)
MF C9 H15 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]-1-(cyclopropylmethyl)-N-hydroxy- (9CI)
MF C23 H27 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP', FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentanecarboxamide, N-hydroxy-2-[(4-methoxyphenyl)sulfonyl]-2-(phenylmethyl)-, trans- (9CI)
MF C20 H23 N O5 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-[[(1,1-dimethylethoxy)amino]carbonyl]-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H38 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanoic acid, 3-[[4-(4-chlorophenoxy)phenyl]thio]-2,2-dimethyl- (9CI)
MF C17 H17 Cl O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanedioic acid, diethyl ester (9CI)
MF C7 H12 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-[2-(1,1-dimethylethoxy)-2-oxoethylidene]-, phenylmethyl ester (9CI)
MF C19 H25 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, 1-cyclopropyl-N-(1,1-dimethylethoxy)-4-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI)
MF C26 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-(2-naphthalenylsulfonyl)- (9CI)
MF C20 H19 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetamide, N-hydroxy-1-[(4-phenoxyphenyl)sulfinyl]- (9CI)
MF C19 H21 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-(4-bromophenoxy)- (9CI)
MF C12 H9 Br O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-[[(dimethylamino)sulfonyl]amino]-N-(1,1-dimethylethoxy)-3-[(4-phenoxyphenyl)sulfonyl]-, (R)- (9CI)
MF C21 H29 N3 O7 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Alaninamide, L-valyl-N-(1,1-dimethylethoxy)-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C24 H33 N3 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, 4-[[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy- (9CI)
MF C18 H19 Cl N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 4-[[4-(4-fluorophenoxy)phenyl]sulfonyl]-N-hydroxy- (9CI)
MF C19 H21 F N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]tetrahy
dro-N-hydroxy- (9CI)
MF C19 H20 Cl N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Boronic acid, 2-thienyl- (9CI)
MF C4 H5 B O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Piperidinedicarboxylic acid, 4-(hydroxymethyl)-, 1-(1,1-dimethylethyl) ester (9CI)
MF C12 H21 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 1-(cyclopropylmethyl)-4-[[4-(4-fluorophenoxy)phenyl]sulfonyl]-N-hydroxy- (9CI)
MF C23 H27 F N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C19 H21 N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-bromophenoxy)phenyl]sulfonyl]methyl]tetr
ahydro-N-hydroxy- (9CI)
MF C19 H20 Br N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl) 4-ethyl ester
(9CI)
MF C13 H23 N O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-(1,1-dimethylethoxy)-
3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C32 H39 N3 O8 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 1-(cyclopropylmethyl)-N-hydroxy-4-[(4-
phenoxyphenyl)sulfonyl]- (9CI)
MF C23 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI)
MF C19 H20 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[(4-methoxyphenyl)sulfonyl]- (9CI)
MF C17 H19 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, N-(1,1-dimethylethoxy)tetrahydro-4-[[[4-(4-

pyridinyloxy)phenyl]thio]methyl]- (9CI)
MF C22 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [(3S)-2-oxo-3-oxetanyl]-, phenylmethyl ester (9CI)
MF C11 H11 N O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetic acid, 4-[(4-phenoxyphenyl)thio]-1-[(phenylmethoxy)carbonyl]- (9CI)
MF C27 H27 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Cysteine, S-(4-phenoxyphenyl)-N-[(phenylmethoxy)carbonyl]- (9CI)
MF C23 H21 N O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-N-
hydroxy-, monohydrochloride (9CI)
MF C19 H21 Cl N2 O5 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]sulfonyl]

methyl]-N-(1,1-dimethylethoxy)tetrahydro- (9CI)
MF C22 H27 Cl N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]tet
rahydro-, methyl ester (9CI)
MF C20 H21 Cl O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbonochloridic acid, phenylmethyl ester (9CI)
MF C8 H7 Cl O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-(4-pyridinyloxy)- (9CI)

MF C11 H9 N O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, N-(1,1-dimethylethoxy)-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-1-(3-pyridinylcarbonyl)- (9CI)
MF C29 H33 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentanebutanamide, N-hydroxy-.beta.-[(4-methoxyphenyl)sulfonyl]- (9CI)
MF C16 H23 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfinyl]methyl]tet
rahydro-N-hydroxy- (9CI)
MF C19 H20 Cl N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester (9CI)
MF C11 H19 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetic acid, tetrahydro-4-[(4-phenoxyphenyl)thio]- (9CI)
MF C19 H20 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl
]tetrahydro-, methyl ester (9CI)
MF C20 H21 Cl O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-N-
hydroxy-1-(2-pyridinylmethyl)-, monohydrochloride (9CI)
MF C25 H26 Cl N3 O5 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide,
4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-
hydroxy- (9CI)
MF C19 H20 Cl N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-bromophenoxy)phenyl]thio]methyl]tetrahyd
ro-N-hydroxy- (9CI)
MF C19 H20 Br N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Pyridine, 3-(chloromethyl)-, hydrochloride (8CI, 9CI)
MF C6 H6 Cl N . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 7-Oxa-2-azaspiro[3.5]nonane-2-carboxylic acid, 1-oxo-, 1,1-dimethylethyl ester (9CI)
MF C12 H19 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-1-methyl-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C20 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Thiopyran-4-acetamide, tetrahydro-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-, 1,1-dioxide (9CI)
MF C19 H21 N O7 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI)
MF C19 H21 N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, 4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]tetrahydro- (9CI)
MF C19 H19 Cl O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Boronic acid, phenyl- (9CI)
MF C6 H7 B O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Alaninamide, L-valyl-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C20 H25 N3 O6 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, N-(1,1-dimethylethoxy)-4-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI)
MF C23 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-(phenylsulfonyl)- (9CI)
MF C16 H17 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 3-[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]thio]-N-(1,1-dimethylethoxy)-2,2-dimethyl- (9CI)
MF C20 H25 Cl N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-phenoxy- (9CI)
MF C12 H10 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanoic acid, .beta.-[[4-(phenylthio)phenyl]sulfonyl]- (9CI)
MF C22 H20 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [2-[(1,1-dimethylethoxy)amino]-2-oxo-1-[[(4-phenoxyphenyl)sulfonyl]methyl]ethyl]-, phenylmethyl ester, (R)- (9CI)
MF C27 H30 N2 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-N-

hydroxy-1-(3-pyridinylcarbonyl)-, monohydrochloride (9CI)
MF C25 H24 Cl N3 O6 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C19 H22 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-bromophenoxy)phenyl]thio]methyl]tetr
ahydro-, ethyl ester (9CI)
MF C21 H23 Br O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro- (8CI, 9CI)
MF C6 H10 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-(hydroxymethyl)-, ethyl ester (9CI)
MF C9 H16 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidineacetic acid, 4-[2-(hydroxyamino)-2-oxoethyl]-4-[(4-phenoxyphenyl)sulfonyl]-, ethyl ester (9CI)
MF C23 H28 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetamide, N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]- (9CI)
MF C14 H19 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tet
rahydro-N-hydroxy- (9CI)
MF C19 H20 Cl N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-, ethyl ester (9CI)
MF C8 H14 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Dioxaspiro[4.5]decane-8-acetamide, N-hydroxy-8-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C22 H25 N O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-3-(phenylmethyl)- (9CI)
MF C26 H25 Cl O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-bromophenoxy)phenyl]sulfonyl]methyl]
tetrahydro- (9CI)
MF C19 H19 Br O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]- (9CI)
MF C14 H20 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetamide, N-(1,1-dimethylethoxy)-1-[(4-phenoxyphenyl)thio]-(9CI)
MF C23 H29 N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanoic acid, 3-chloro-2,2-dimethyl- (9CI)
MF C5 H9 Cl O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, 4-(bromomethyl)tetrahydro-, ethyl ester (9CI)
MF C9 H15 Br O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide,
1-(cyclopropylmethyl)-4-[(4-phenoxyphenyl)sulfonyl]-
(9CI)
MF C23 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclohexanecarboxamide, N-hydroxy-2-[(4-methoxyphenyl)sulfonyl]-, trans-
(9CI)
MF C14 H19 N O5 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-[4-(3-

thienyl)phenoxy]phenyl]sulfonyl]methyl]- (9CI)
MF C23 H23 N O6 S2

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid,
4-[[[4-(4-fluorophenoxy)phenyl]thio]methyl]tet
rahydro- (9CI)
MF C19 H19 F O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzene, 1-bromo-4-phenoxy- (9CI)
MF C12 H9 Br O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-[[(dimethylamino)sulfonyl]amino]-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, (R)- (9CI)
MF C17 H21 N3 O7 S2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-(1,1-dimethylethoxy)-1-methyl-4-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C24 H32 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, .beta.-([1,1'-biphenyl]-4-ylsulfonyl)-N-hydroxy- (9CI)
MF C22 H21 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide, 4-[[4-(4-fluorophenoxy)phenyl]thio]tetrahydro-N-hydroxy- (9CI)
MF C19 H20 F N O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-(carboxymethylene)-, 1-(phenylmethyl ester)
(9CI)
MF C15 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-amino-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, (2R)-(9CI)
MF C15 H16 N2 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-amino-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride, (2R)- (9CI)
MF C15 H16 N2 O5 S . Cl H

Absolute stereochemistry.



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]-, monohydrochloride (9CI)
MF C18 H20 N2 O6 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid, 4-[2-(hydroxyamino)-2-oxoethyl]-4-[(4-methoxyphenyl)sulfonyl]-, phenylmethyl ester (9CI)
MF C22 H26 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-[[[4-(4-pyridinyloxy)phenyl]thio]methyl]- (9CI)
MF C18 H19 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, diethyl ester (6CI, 7CI, 8CI, 9CI)
MF C11 H18 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-(hydroxymethyl)- (9CI)
MF C7 H12 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-1-(3-pyridinylmethyl)- (9CI)
MF C25 H27 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclohexaneacetamide, N-hydroxy-1-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C20 H23 N O5 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-fluorophenoxy)phenyl]sulfonyl]methyl]tet
rahydro-N-hydroxy- (9CI)
MF C19 H20 F N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Proteinase, matrix metallo- (9CI)
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidineacetic acid, 4-[2-[(1,1-dimethylethoxy)amino]-2-oxoethyl]-4-
[(4-phenoxyphenyl)sulfonyl]-, ethyl ester (9CI)
MF C27 H36 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 2-[[(dimethylamino)sulfonyl]amino]-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride, (R)- (9CI)
MF C17 H21 N3 O7 S2 . Cl H

Absolute stereochemistry.



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-[[[4-[4-(3-thienyl)phenoxy]phenyl]sulfonyl]methyl]- (9CI)
MF C23 H22 O6 S2

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[(3-methoxyphenyl)sulfonyl]- (9CI)
MF C17 H19 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Piperidinecarboxylic acid,
4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]-4-
[[(1,1-dimethylethoxy)amino]carbonyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H37 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Pyridinecarbonyl chloride, hydrochloride (9CI)
MF C6 H4 Cl N O . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, tetrahydro-4-[[[(4-
methylphenyl)sulfonyl]oxy]methyl]-, ethyl ester (9CI)
MF C16 H22 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide,
1-acetyl-4-[[4-(4-fluorophenoxy)phenyl]sulfonyl]-N-
hydroxy- (9CI)
MF C21 H23 F N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclohexaneacetamide, N-hydroxy-4-oxo-1-[(4-phenoxyphenyl)sulfonyl]-
(9CI)
MF C20 H21 N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide, N-(1,1-dimethylethoxy)tetrahydro-4-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]- (9CI)
MF C22 H28 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1,4-Piperidinedicarboxylic acid, 4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) ester (9CI)
MF C24 H28 Cl N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Ethane, 1,1'-oxybis[2-chloro- (9CI)
MF C4 H8 Cl2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-(4-fluorophenoxy)- (9CI)
MF C12 H9 F O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, N-(1,1-dimethylethoxy)-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-1-(3-pyridinylmethyl)- (9CI)
MF C29 H35 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[[4-[2-(4-methoxyphenyl)ethenyl]phenyl]sulfonyl]- (9CI)
MF C25 H25 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide,
4-[[4-(4-fluorophenoxy)phenyl]sulfinyl]tetrahydro-N-
hydroxy- (9CI)
MF C19 H20 F N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenethiol, 4-(4-chlorophenoxy)- (9CI)
MF C12 H9 Cl O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentaneacetic acid, 1-[(4-phenoxyphenyl)thio]- (9CI)
MF C19 H20 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Alaninamide, L-valyl-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI)
MF C20 H25 N3 O6 S . Cl H

Absolute stereochemistry.



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 3-[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl- (9CI)
MF C16 H17 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]-N-hydroxy-(9CI)
MF C19 H21 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-(4-fluorophenoxy)phenyl]thio]methyl]tetrahydro-N-hydroxy- (9CI)
MF C19 H20 F N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Boronic acid, 3-thienyl- (9CI)
MF C4 H5 B O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 2,7-Dioxaspiro[3.5]nonan-1-one (9CI)
MF C7 H10 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetamide, 1-ethyl-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-(9CI)
MF C21 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-acetamide, 4-[[4-(4-fluorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI)
MF C19 H20 F N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 3-[[4-(4-chlorophenoxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl- (9CI)
MF C17 H18 Cl N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidineacetic acid, 4-[(4-phenoxyphenyl)thio]-, hydrochloride (9CI)
MF C19 H21 N O3 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2-Propanone (9CI)
MF C3 H6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-hydroxy-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
MF C28 H31 N3 O8 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[[4-(2-phenylethenyl)phenyl]sulfonyl]- (9CI)
MF C24 H23 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanamide, N-hydroxy-.beta.-[[4-(phenylthio)phenyl]sulfonyl]- (9CI)
MF C22 H21 N O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxamide,
4-[[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]thio]meth
yl]-N-(1,1-dimethylethoxy)tetrahydro- (9CI)
MF C22 H27 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4H-Pyran-4-one, tetrahydro- (6CI, 7CI, 8CI, 9CI)
MF C5 H8 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenebutanoic acid, .beta.-[(4-bromophenyl)sulfonyl]- (9CI)
MF C16 H15 Br O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [2-[(1,1-dimethylethoxy)amino]-2-oxo-1-[[(4-phenoxyphenyl)thio]methyl]ethyl]-, phenylmethyl ester, (R)- (9CI)
MF C27 H30 N2 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4-Piperidinecarboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-1-(cyclopropylmethyl)-N-hydroxy-, monohydrochloride (9CI)
MF C23 H27 Cl N2 O5 S . Cl H



● HCl

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Propanamide, 3-[[4-[(5-chloro-2-pyridinyl)oxy]phenyl]sulfonyl]-N-(1,1-dimethylethoxy)-2,2-dimethyl- (9CI)
MF C20 H25 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Pyran-4-carboxylic acid, 4-[[[4-(4-chlorophenoxy)phenyl]thio]methyl]tetrahydro-, ethyl ester (9CI)
MF C21 H23 Cl O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 174 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Benzene, 1-ethenyl-4-methoxy- (9CI)
MF C9 H10 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.24	6.40

STN INTERNATIONAL LOGOFF AT 10:59:34 ON 07 FEB 2002

C:\STNEXP4\QUERIES\09530966.str





chain nodes :
1 2 3 4 5 6 7 8 9 11 12 15
chain bonds :
1-2 2-3 3-5 3-4 5-6 5-12 5-15 6-7 7-8 7-9 7-11
exact/norm bonds :
2-3 3-4 5-12 5-15 6-7 7-8 7-9 7-11
exact bonds :
1-2 3-5 5-6

G1:Cy,Ak

G2:O,N,X

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 11:CLASS 12:CLASS 15:CLASS

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:72030 CAPLUS
DOCUMENT NUMBER: 136:134761
TITLE: Preparation of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs)
INVENTOR(S): Mantegani, Sergio; Bissolino, Pierluigi; Abrate, Francesca; Cremonesi, Paolo; Perrone, Ettore
PATENT ASSIGNEE(S): Pharmacia + Upjohn S.p.A., Italy
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006215	A1	20020124	WO 2001-EP7736	20010705

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-17435 A 20000714
OTHER SOURCE(S): MARPAT 136:134761
GI



I

AB The title compds. [I; X = NHOH, OH; R1 = OPh, SPh, SHet, Hyd, CH2Hyd; Het = heterocyclic ring; Hyd = substituted hydantoin-3-yl ring; A = Ph, Het, condensed Ph ring; R2 = H, Me; or R2 represents a methylene bridge connecting the N atom to the ortho position of said A to form a 5-membered lactam] or their salts which are inhibitors of matrix metallo-proteinases (MMPs) and are therefore useful in the prevention, control and treatment

of diseases in which MMPs are involved, were prepd. E.g., a multi-step synthesis of I [A = 4-ClC6H4; X = OH; R1 = (3,4,4-trimethylhydantoin-1-yl)CH2; R2 = H] which showed Ki of 14.7 nM against MMP-2, was given.

IT **391903-52-9P 391903-53-0P 391903-54-1P**
391903-55-2P 391903-56-3P 391903-57-4P
391903-58-5P 391903-59-6P 391903-60-9P
391903-61-0P 391903-62-1P 391903-63-2P
391903-64-3P 391903-65-4P 391903-66-5P
391903-67-6P 391903-68-7P 391903-69-8P
391903-70-1P 391903-71-2P 391903-72-3P
391903-73-4P 391903-74-5P 391903-76-7P
391903-77-8P 391903-78-9P 391903-79-0P
391904-13-5P 391904-15-7P 391904-16-8P
391904-18-0P 391904-19-1P 391904-22-6P
391904-23-7P 391904-24-8P 391904-25-9P
391904-26-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acids as inhibitors of matrix metallo-proteinases (MMPs))

RN 391903-52-9 CAPLUS

CN 1-Imidazolidinebutanoic acid, .alpha.-[[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 391903-53-0 CAPLUS
CN 1-Imidazolidinebutanoic acid, .alpha.-[[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 391903-54-1 CAPLUS
CN 1-Imidazolidinebutanoic acid, .alpha.-hydroxy-.alpha.-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]methyl]-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 391903-55-2 CAPLUS
CN Propanoic acid,
3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-56-3 CAPLUS
CN Propanoic acid,
2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]
methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 391903-57-4 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-
pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-58-5 CAPLUS
CN Propanoic acid,
3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl
]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-59-6 CAPLUS
CN Propanoic acid,
3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-
hydroxy-2-[(phenylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391903-60-9 CAPLUS
CN Propanoic acid,
3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-61-0 CAPLUS
CN Propanoic acid,
3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-62-1 CAPLUS
CN Propanoic acid,
3-[[4-[(4-cyanobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-63-2 CAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[(4-
pyridinylcarbonyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-64-3 CAPLUS
CN Propanoic acid,
3-[[4-[(4-bromobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-65-4 CAPLUS
CN Propanoic acid,
3-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]sulfonyl]-2-
hydroxy-2-(phenoxymethyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 391903-66-5 CAPLUS
CN Propanoic acid,
2-hydroxy-2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]
methyl]-3-phenoxy- (9CI) (CA INDEX NAME)



RN 391903-67-6 CAPLUS
CN Propanoic acid,
3-[[4-[(1,3-benzodioxol-5-ylcarbonyl)amino]phenyl]sulfonyl
]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-68-7 CAPLUS
CN Propanoic acid, 3-[[4-(benzoylamino)phenyl]sulfonyl]-2-hydroxy-2-
(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-69-8 CAPLUS
CN Propanoic acid,
3-[[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]sulfonyl]-
2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-70-1 CAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)methylamino]phenyl]sulfonyl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391903-71-2 CAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-thiazolylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-72-3 CAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391903-73-4 CAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391903-74-5 CAPLUS
CN Propanoic acid, 3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-[[(4-fluorophenyl)thio]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 391903-76-7 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 391903-77-8 CAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-78-9 CAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391903-79-0 CAPLUS
CN Propanoic acid, 3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-[[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 391904-13-5 CAPLUS
CN Propanoic acid,
3-[[4-[(1H-benzotriazol-5-ylcarbonyl)amino]phenyl]sulfonyl
]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391904-15-7 CAPLUS
CN Propanoic acid,
3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
[(phenylthio)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391904-16-8 CAPLUS
CN Propanoic acid,
3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
[(2-thiazolylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391904-18-0 CAPLUS
CN Propanoic acid,
3-[[4-[(4-chlorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
[(2-pyridinylthio)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 391904-19-1 CAPLUS
CN Propanoic acid,
3-[[4-[(4-fluorobenzoyl)amino]phenyl]sulfonyl]-2-hydroxy-2-
[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 391904-22-6 CAPLUS
CN Propanoic acid, 2-hydroxy-2-(phenoxymethyl)-3-[[4-[[4-(1-
pyrrolidinyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-23-7 CAPLUS
CN Propanoic acid,
3-[[4-[[(6-chloro-3-pyridinyl)carbonyl]amino]phenyl]sulfon
yl]-2-hydroxy-2-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 391904-24-8 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[(4-
propoxybenzoyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-25-9 CAPLUS

CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 391904-26-0 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:746581 CAPLUS
DOCUMENT NUMBER: 136:167154
TITLE: .alpha.-Alkyl-.alpha.-amino-.beta.-sulfone hydroxamates as potent MMP inhibitors that spare MMP-1
AUTHOR(S): Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C.
CORPORATE SOURCE: Departments of Medicinal Chemistry and Inflammation-Oncology, Pharmacia Research & Development, Skokie, IL, 60077, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(20), 2723-2725
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of .alpha.-alkyl-.alpha.-amino-.beta.-sulfonyl hydroxamates HONHCOCR1(NR2R3)CH2SO2C6H4XPh-4 [R1 = Me, R2 = H, Ac, Me, Et, CH2Ph, CH2CH2Ph, 3,4-methylenedioxybenzyl, 2-naphthylmethyl, propargyl, pyrrolidinoacetyl, R3 = H, X = O; R1-R3 = Me, X = O; R1 = Me, R2 = H, Ac,

R3 = H, X = S; R1 = Ph, R2 = Bz, H, R3 = H, X = O; R1R2 = (CH2)3, R3 = propargyl, X = O] was prepd. and evaluated for potency vs. MMP-2 and MMP-13, and for selectivity vs. MMP-1. Low nanomolar potency was obtained with selectivity vs. MMP-1 ranging from >10 to >1000. Selected compds. were orally bioavailable.

IT **397330-26-6P 397330-28-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(.alpha.-alkyl-.alpha.-amino-.beta.-sulfonyl hydroxamates as potent MMP inhibitors that spare MMP-1)

RN 397330-26-6 CAPLUS
CN Alanine, 2-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 397330-28-8 CAPLUS
CN Alanine, N-acetyl-2-[[[4-(phenylthio)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:730698 CAPLUS
DOCUMENT NUMBER: 135:289056
TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Moormann, Alan E.; Pitzele, Barnett S.; Promo, Michelle A.; Schartman, Richard R.; Snyder, Jeffrey S.; Trivedi, Mahima; Tsymbalov, Sofya

PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072703	A1	20011004	WO 2001-US9433	20010323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019563	A1	20020214	US 2001-816577	20010323

PRIORITY APPLN. INFO.: US 2000-191923P P 20000324
OTHER SOURCE(S): MARPAT 135:289056

AB The invention relates to S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine (1) or its pharmaceutically acceptable salts for use as nitric oxide synthase (NOS) inhibitors. Thus, 1.2HCl was prepd. by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH2CH2Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compd. 1.2HCl showed hiNOS, hecNOS, hncNOS, and human cartilage IC50 values 3.1, 77, 15 .mu.M, and 0.7 .mu.M, resp.

IT **364067-25-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidino compds. useful as nitric oxide synthase inhibitors)

RN 364067-25-4 CAPLUS
CN L-Alanine, 3-[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:730697 CAPLUS
DOCUMENT NUMBER: 135:273215
TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Manning, Pamela T.; Mao, Michael; Moormann, Alan E.; Pitzele, Barnett S.; Promo, Michelle A.; Schartman, Richard R.; Scholten, Jeffrey A.; Snyder, Jeffrey S.; Toth, Mihaly V.; Trivedi, Mahima; Tsymbalov, Sofya; Tjoeng, Foe Siong
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072702	A2	20011004	WO 2001-US9431	20010323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019563	A1	20020214	US 2001-816577	20010323

PRIORITY APPLN. INFO.: US 2000-191923P P 20000324
OTHER SOURCE(S): MARPAT 135:273215
AB Amidino compds. R11N:CR13NR12CR9R10CR1R7-X-CR5R6CR2(NR3R4)COR8 [X = S, SO,

SO2; R1, R5, R6, R7 = H, halo, alkyl (alkyl and other groups may be substituted), alkenyl, alkynyl, alkoxyalkyl; R2 = alkyl, alkenyl, alkynyl, alkoxyalkyl, alkylthioalkyl; R3 = H, OH, CHO, alkanoyl, CO2H, C(O)SH or alkyl esters; R8 = OH, alkoxy, an amino or alkylamino group or R3 and R8 may form a ring; R4 = H, CO2H, carbalkoxy; R9, R10 = H, alkyl, alkenyl, alkynyl, alkoxyalkyl; R11, R12 = H, OH, CO2H, C(O)SH or esters or R11 and R12 may form a ring; R13 = alkyl (with provisos)] or their salts were prepd. as nitric oxide synthase (NOS) inhibitors. Thus, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine dihydrochloride (1) was prepd. by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH2CH2Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compd. 1 showed hiNOS, hecNOS, hncNOS, and human cartilage IC50 values 3.1, 77, 15 .mu.M, and 0.7 .mu.M, resp.

IT **364067-25-4P 364068-52-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidino compds. useful as nitric oxide synthase inhibitors)

RN 364067-25-4 CAPLUS

CN L-Alanine, 3-[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 364068-52-0 CAPLUS

CN L-Alanine, 3-[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396841 CAPLUS
DOCUMENT NUMBER: 135:5449
TITLE: Preparation of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its use as a matrix metalloproteinase inhibitor in the treatment of cancer
INVENTOR(S): Bissolino, Pierluigi; Mantegani, Sergio; Orzi, Fabrizio; Jabes, Daniela; Alzani, Rachele; D'anello, Matteo; Perrone, Ettore
PATENT ASSIGNEE(S): Pharmacia + Upjohn S.P.A., Italy
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038301	A1	20010531	WO 2000-EP10837	20001101

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-27453 A 19991119
OTHER SOURCE(S): CASREACT 135:5449

AB (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts, useful as a matrix metalloproteinase inhibitor in the treatment of cancers, is prepd. along with its salts.

IT **226419-98-3P 341498-84-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in the prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts as matrix metalloproteinase inhibitors useful in the treatment of cancers)

RN 226419-98-3 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 341498-84-8 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, (2R)-, compd. with (.alpha.S)-.alpha.-[(1R)-1-(methylamino)ethyl]benzenemethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 341498-83-7
CMF C22 H19 Cl O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 321-98-2
CMF C10 H15 N O

Absolute stereochemistry. Rotation (+).



IT **341498-83-7P 341498-89-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts as matrix metalloproteinase inhibitors useful in the treatment of cancers)
RN 341498-83-7 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 341498-89-3 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, monosodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT **341498-92-8P 341498-95-1P 341498-98-4P**
341499-01-2P 341499-04-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (R)-3-(4-chlorobiphenylsulfonyl)-2-hydroxy-2-(phenylthio)methylpropionic acid and its salts as matrix metalloproteinase inhibitors useful in the treatment of cancers)
RN 341498-92-8 CAPLUS
CN L-Arginine, mono[(2R)-3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]propanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 341498-83-7
CMF C22 H19 Cl O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2
CDES 5:L

Absolute stereochemistry.



RN 341498-95-1 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-,
(2R)-3-[(4'-chloro[1,1'-biphenyl]-4-
yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]propanoate (salt) (9CI) (CA
INDEX NAME)

CM 1

CRN 341498-83-7
CMF C22 H19 Cl O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 6284-40-8
CMF C7 H17 N O5
CDES *

Absolute stereochemistry.



RN 341498-98-4 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, monopotassium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



K

RN 341499-01-2 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, calcium salt (2:1), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

RN 341499-04-5 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]-, magnesium salt (2:1), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Mg

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:354468 CAPLUS

DOCUMENT NUMBER: 131:18833
TITLE: Preparation of .alpha.-hydroxy, -amino, and halo derivatives of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
INVENTOR(S): Warpehoski, Martha A.; Mitchell, Mark Allen; Harper, Donald E.; Maggiora, Linda Louise
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926909	A2	19990603	WO 1998-IB2154	19981118
WO 9926909	A3	19990826		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9925405	A1	19990615	AU 1999-25405	19981118
EP 1037868	A2	20000927	EP 1998-966869	19981118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9814699	A	20001003	BR 1998-14699	19981118
JP 2001524462	T2	20011204	JP 2000-522069	19981118
NO 2000002505	A	20000630	NO 2000-2505	20000515

PRIORITY APPLN. INFO.: US 1997-72655P P 19971121
WO 1998-IB2154 W 19981118

OTHER SOURCE(S): MARPAT 131:18833
GI



I

AB The title compds. [I; R1 = C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; R2 = C1-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; Y = OH, NR9R10, F; R9, R10 = H, COR3, CO2R3, etc.; R3 = H, cycloalkyl, alkyl, etc.], inhibitors of matrix metalloproteinases which are useful in treating osteoarthritis, rheumatoid arthritis, septic arthritis, osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, or

asthma, were prepd. E.g., a 7-step synthesis of I [R1 = 4-PhC6H4; R2 = 4-MeOC6H4SO2CH2; Y = OH] which showed Ki of 0.074 .mu.M and 0.0019 .mu.M against stromelysin and gelatinase, resp.

IT **226419-90-5P 226419-91-6P 226419-92-7P**
226419-93-8P 226419-94-9P 226419-95-0P
226419-96-1P 226419-97-2P 226419-98-3P
226419-99-4P 226420-00-4P 226420-01-5P
226420-02-6P 226420-03-7P 226420-04-8P
226420-05-9P 226420-06-0P 226420-07-1P
226420-08-2P 226420-09-3P 226420-10-6P
226420-11-7P 226420-12-8P 226420-13-9P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .alpha.-hydroxy, -amino, and halo derivs. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 226419-90-5 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-3-butyl-.alpha.-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 226419-91-6 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 226419-92-7 CAPLUS
CN Propanoic acid, 3-[(4-butoxyphenyl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 226419-93-8 CAPLUS
CN Propanoic acid, 3-[(4-butoxyphenyl)sulfonyl]-2-hydroxy-2-[[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 226419-94-9 CAPLUS
CN Pentonic acid, 2-C-[[(4-butoxyphenyl)sulfonyl]methyl]-3,5-dideoxy-4-S-(phenylmethyl)-4-thio- (9CI) (CA INDEX NAME)



RN 226419-95-0 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226419-96-1 CAPLUS

CN 1-Imidazolidinepropanoic acid,
3-butyl-.alpha.-[[(4'-chloro[1,1'-biphenyl]-
4-yl)sulfonyl]methyl]-.alpha.-hydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226419-97-2 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-.alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226419-98-3 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 226419-99-4 CAPLUS

CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)



RN 226420-00-4 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 226420-01-5 CAPLUS
CN Propanoic acid, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-hydroxy-2-[[[(5-methyl-3-isoxazolyl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 226420-02-6 CAPLUS
CN Pentonic acid,
2-C-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3,4,5-trideoxy-4-(3-methyl-2,5-dioxo-1-imidazolidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226420-03-7 CAPLUS
CN Pentonic acid, 2-C-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-3,5-dideoxy-4-S-(phenylmethyl)-4-thio- (9CI) (CA INDEX NAME)



RN 226420-04-8 CAPLUS
CN 1-Imidazolidinepropanoic acid,
.alpha.-hydroxy-3-methyl-2,5-dioxo-.alpha.-
[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-05-9 CAPLUS
CN 1-Imidazolidinepropanoic acid, 3-butyl-.alpha.-hydroxy-2,5-dioxo-.alpha.-
[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-06-0 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo-.alpha.-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-07-1 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[[(4-phenoxyphenyl)sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 226420-08-2 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[[(4-phenoxyphenyl)sulfonyl]methyl]-3-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 226420-09-3 CAPLUS
CN Pentonic acid, 3,4,5-trideoxy-4-(3-methyl-2,5-dioxo-1-imidazolidinyl)-2-C-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-10-6 CAPLUS

CN Pentonic acid, 3,5-dideoxy-4-S-(1-methyl-1H-imidazol-2-yl)-2-C-[[(4-phenoxyphenyl)sulfonyl]methyl]-4-thio- (9CI) (CA INDEX NAME)



RN 226420-11-7 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo-.alpha.-[[[4-(4-pyridinyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 226420-12-8 CAPLUS
CN Propanoic acid, 2-hydroxy-2-[(phenylthio)methyl]-3-[[4-(4-pyridinyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 226420-13-9 CAPLUS
CN 1-Imidazolidinepropanoic acid, .alpha.-hydroxy-3,4,4-trimethyl-2,5-dioxo-.alpha.-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **226420-18-4P 226420-21-9P 226420-22-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of .alpha.-hydroxy, -amino, and halo derivs. of .beta.-sulfonyl
hydroxamic acids as matrix metalloproteinases inhibitors)
RN 226420-18-4 CAPLUS
CN Propanoic acid, 3-([1,1'-biphenyl]-4-ylsulfonyl)-2-hydroxy-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-21-9 CAPLUS
CN Propanoic acid, 3-(benzoylamino)-2-hydroxy-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226420-22-0 CAPLUS
CN Propanoic acid, 2-hydroxy-3-[(4-methoxybenzoyl)amino]-2-[[(4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:612095 CAPLUS

DOCUMENT NUMBER: 129:244921
TITLE: Preparation of aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds as matrix metalloprotease inhibitors
INVENTOR(S): Freskos, John N.; Boehm, Terri L.; Mischke, Brent V.; Heintz, Robert M.; Mcdonald, Joseph J.; Decrescenzo, Gary A.; Howard, Susan C.
PATENT ASSIGNEE(S): Monsanto Company, USA
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839326	A1	19980911	WO 1998-US4277	19980304
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9864478	A1	19980922	AU 1998-64478	19980304
AU 737329	B2	20010816		
EP 984959	A1	20000315	EP 1998-910177	19980304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9808150	A	20000328	BR 1998-8150	19980304

PRIORITY APPLN. INFO.: US 1997-35182P P 19970304
WO 1998-US4277 W 19980304

OTHER SOURCE(S): MARPAT 129:244921

AB The title compds. HONHC(O)C(OH)(R2)CH2SO2R1 [I; R2 = H, C1-4 alkyl, C1-4 haloalkyl, etc.; R1 = 5-6 membered cycloalkyl, heterocyclyl, aryl, etc.] which inter alia inhibit matrix metalloprotease activity, were prepd. Thus, multi-step synthesis of I [R1 = 4-PhOC6H4; R2 = Me] which showed 51.9% inhibition of angiogenesis in the cornea of a mouse, was described.

IT **213184-20-4P 213184-29-3P 213184-51-1P**
213184-61-3P 213184-63-5P 213184-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. sulfonyl alpha-hydroxy hydroxamic acid compds. as matrix metalloprotease inhibitors)

RN 213184-20-4 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-29-3 CAPLUS
CN Propanoic acid, 3-[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 213184-51-1 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[(4-nitrophenyl)sulfonyl]- (9CI) (CA
INDEX NAME)



RN 213184-61-3 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-63-5 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(3-

methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-65-7 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(4-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:532307 CAPLUS
DOCUMENT NUMBER: 122:278041
TITLE: Photographic couplers having a ballast containing a sulfone or sulfoxide group
INVENTOR(S): Krishnamurthy, Sundaram; Cowan, Stanley W.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5399467	A	19950321	US 1993-144754	19931029
EP 653676	A1	19950517	EP 1994-203077	19941022
EP 653676	B1	19991229		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07181647	A2	19950721	JP 1994-264772	19941028

PRIORITY APPLN. INFO.: US 1993-144754 19931029
OTHER SOURCE(S): MARPAT 122:278041
AB Novel photog. Ag halide materials contain dye-forming couplers K-NHC(O)C(R2)(-L_R)SOn-R1 [n = 1 or 2; R2 = H, substituent; R and R1 = substituent; L is selected from the group consisting of O, S, Se, Te,

Si(R5)2, NR5, PR5, P(O)(R5)2 and NR5SO2; (R5 = H, alkyl or aryl); and K is a coupler moiety selected from the group consisting of pyrazolone, phenol, and naphthol]. The couplers exhibit increased coupling activity, and provide formation of dyes having improved max. magenta image dye d., contrast, and development speed.

IT **162849-51-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(photog. couplers having ballast contg. sulfone or sulfoxide group)

RN 162849-51-6 CAPLUS
CN Butanoic acid, 2-[(4-methylphenyl)sulfonyl]-2-(3-pentadecylphenoxy)-(9CI)
(CA INDEX NAME)



L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:640883 CAPLUS
DOCUMENT NUMBER: 119:240883
TITLE: Metabolism of Casodex in laboratory animals
AUTHOR(S): Boyle, G. W.; McKillop, D.; Phillips, P. J.; Harding, J. R.; Pickford, R.; McCormick, A. D.
CORPORATE SOURCE: Saf. Med. Dep., ICI Pharm., Alderley Park/Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Xenobiotica (1993), 23(7), 781-98
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Casodex, a non-steroidal antiandrogen, was eliminated primarily in feces by rat, mouse, rabbit and dog. Rat, mouse and rabbit eliminated 20-30% of a single oral dose (8-25 mg/kg) in urine; only 3-4% was excreted in urine by dog (2.5 mg/kg). Oral absorption was about 80% in rat, mouse, rabbit and dog. Most of the dose was recovered in 48 h from rat, mouse and rabbit. In rat, <1% of the dose was exhaled as 14CO2 and <1% remained in the carcass after 7 days. Recovery from dog was incomplete in 4 days but consistent with the long plasma elimination half-life of 7-7.5 days. Casodex was eliminated from rat plasma with a half-life of 17-21 h. Examn. of urine indicated extensive metab. of Casodex and showed a marked species difference. In rat, mouse and dog. Casodex was cleaved at the amide to yield a carboxylic acid and an arom. amine which subsequently underwent ring hydroxylation with sulfate conjugation. In rabbit, the major urinary metabolite was Casodex glucuronide, conjugated on the tertiary hydroxyl. The major component in feces of all species was unchanged Casodex; some hydroxy-Casodex was also obsd. in rat feces. Anal. of rat and dog bile indicated that Casodex and hydroxy-Casodex were

eliminated in bile primarily as glucuronide conjugates.

IT **151262-57-6**
RL: FORM (Formation, nonpreparative)
(formation of, as Casodex metabolite, species differences in)

RN 151262-57-6 CAPLUS

CN Propanoic acid, 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:614094 CAPLUS

DOCUMENT NUMBER: 111:214094

TITLE: Chemistry of novel compounds with a multifunctional carbon structure. 5. Molecular design of versatile building blocks for aliphatic monofluoro molecules by manipulation of multifunctional carbon structure

AUTHOR(S): Takeuchi, Yoshio; Nagata, Kazuhiro; Koizumi, Toru

CORPORATE SOURCE: Fac. Pharm. Sci., Toyama Med. Pharm. Univ., Toyama, 930-01, Japan

SOURCE: J. Org. Chem. (1989), 54(23), 5453-9
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:214094

AB Three kinds of doubly functionalized monofluoromethylene fragments, PhSO2CRFNO2 (R = Me, PhCH2, CH2CO2Et, CH2CH2COMe), PhSO2CRFCO2Et (R = PhCH2, CH2CH2COMe) and O2NCRFCO2Et (I, R = PhCH2 CH2CH2CO2Et, CH2CH2COMe, CHPhCH2COMe, CH2CH2CN) potentially versatile building blocks for the general synthesis of various aliph. monofluoro mols., were prepd. from the corresponding difunctional compds. by monoalkylations and selective fluorinations. The interconversion or reductive removal of each functional group followed by the introduction of the second alkyl groups (R') at the fluorine-bearing carbon atom was examd. I proved to be useful and practical building blocks for conversions to the various monofluoroalkanes.

IT **122876-09-9P 122876-10-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 122876-09-9 CAPLUS

CN Benzenepropanoic acid, .alpha.-fluoro-.alpha.-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 122876-10-2 CAPLUS
CN Hexanoic acid, 2-fluoro-5-oxo-2-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:150945 CAPLUS
DOCUMENT NUMBER: 108:150945
TITLE: Amino acid sulfones: S-benzyl-DL-.alpha.-methylcysteine sulfone
AUTHOR(S): Griffith, Owen W.
CORPORATE SOURCE: Med. Coll., Cornell Univ., New York, NY, 10021, USA
SOURCE: Methods Enzymol. (1987), 143(Sulfur Sulfur Amino Acids), 274-9
CODEN: MENZAU; ISSN: 0076-6879
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis of S-benzyl-DL-.alpha.-methylcysteine sulfone from S-benzyl-.alpha.-methylcysteine by oxidn. is described. In addn. the reductive cleavage of the sulfone with Na/liq. NH3 to give DL-.alpha.-Me cysteinesulfonic acid is detailed. Also, a general method for the prepn. of S-benzyl derivs. of amino acids contg. thiol or disulfide groups is given.
IT **113737-61-4P**, S-Benzyl-DL-.alpha.-methylcysteine sulfone
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reductive cleavage to sulfinic acid deriv.)
RN 113737-61-4 CAPLUS
CN Alanine, 2-methyl-3-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:593881 CAPLUS
DOCUMENT NUMBER: 107:193881
TITLE: Design and synthesis of phosphonate inhibitors of glutamine synthetase
AUTHOR(S): Farrington, G. King; Kumar, Alok; Wedler, Frederick C.
CORPORATE SOURCE: Dep. Chem., Pennsylvania State Univ., University Park, PA, 16802, USA
SOURCE: J. Med. Chem. (1987), 30(11), 2062-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:193881

AB Phosphonates, H2NCR(CO2H)CH2CH2XCH2PO3-2 (I), were designed as chem. stable analogs of the phosphorylated inhibitors, H2NCH(CO2H)CH2CH2R (R = SONHMe, SO2Me, PO3-2, etc). Phosphonates I (R = Me; X = S, SO, SO2) (II) resembled the transiently stable H2NCH(CO2H)CH2CH2SO2Me, whereas I (R = H; X = PO2-) (III) resembled the 2-amino-4-phosphonobutyric acid. When tested as inhibitors of glutamine synthetase (GS) from bacteria, mammals, and plants, III was proved to be the most potent, with a Ki of 7.5 .times. 10-5 M vs. the Escherichia coli enzyme. Anal. of the inhibition data for II suggested that a replacement of the O bridging the tetrahedral S II or phosphinate III and the terminal phosphate with a hydrophobic methylene drastically reduces the enzyme's affinity for inhibitors. Enhanced affinity of GS for III may result from interaction of the neg. charge on the phosphinate with Mn2+ at the active site.

IT **110372-49-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and glutamine synthetase inhibition by)
RN 110372-49-1 CAPLUS
CN Isovaline, 4-[(phosphonomethyl)sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:402717 CAPLUS
DOCUMENT NUMBER: 103:2717
TITLE: The design of fluorescent probes which bind to the active center of guanidinobenzoatase. Application to the location of cells possessing this enzyme
AUTHOR(S): Steven, Frank S.; Griffin, Margaret M.; Al-Ahmad, Rajaa K.
CORPORATE SOURCE: Dep. Biochem., Univ. Manchester, Manchester, UK

SOURCE: Eur. J. Biochem. (1985), 149(1), 35-40
CODEN: EJBCAI; ISSN: 0014-2956
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Cells possessing a known enzymic activity may be located by fluorescent probes designed to act as competitive inhibitors of this enzyme. A series of dansyl N-substituted guanidino derivs. which bind to the active center of guanidinobenzoatase were prepd. 9-Aminoacridine also acted as a competitive inhibitor and behaved similarly to these guanidino derivs. These fluorescent probes were used to locate tumor cells possessing this enzyme in thin sections of fixed tissue by employing fluorescent microscopy.

IT **96425-07-9 96425-10-4**
RL: BIOL (Biological study)
(as fluorescent probe of guanidinobenzoatase active center)

RN 96425-07-9 CAPLUS
CN Lysine, N6-(aminoiminomethyl)-N2,2-bis[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 96425-10-4 CAPLUS
CN Arginine, N2-[1-carboxy-1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethyl]-2-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:178450 CAPLUS
DOCUMENT NUMBER: 102:178450
TITLE: Gas chromatographic separation of enantiomeric sulfur compounds on Chirasil-Val
AUTHOR(S): Bayer, Ernst; Kuesters, Ernst; Nicholson, Graeme J.; Frank, Hartmut
CORPORATE SOURCE: Inst. Org. Chem., Univ. Tuebingen, Tuebingen, D-7400/1, Fed. Rep. Ger.
SOURCE: J. Chromatogr. (1985), 320(2), 393-6
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The gas chromatog. sepn. of sulfoxide antipodes, including aliph. sulfoxides, on quartz fused silica capillaries coated with the chiral silicone phase Chirasil-Val is reported. The compds. were esterified before anal. A flame ionization detector and H carrier gas were used.
IT **95833-67-3 95833-68-4**
RL: ANST (Analytical study); PROC (Process)
(sepn. of, by gas chromatog. on Chirasil-Val)
RN 95833-67-3 CAPLUS
CN L-Isovaline, 4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 95833-68-4 CAPLUS
CN D-Isovaline, 4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1981:569043 CAPLUS
DOCUMENT NUMBER: 95:169043
TITLE: .alpha.-Amino acids as nucleophilic acyl equivalents. V. Sterically directed Michael addition of oxazolin-5-one anions to activated double bonds; synthesis of 1,4-dicarbonyl compounds and .gamma.-oxonitriles
AUTHOR(S): Wegmann, Helmut; Steglich, Wolfgang
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Bonn, Bonn, D-5300, Fed. Rep. Ger.
SOURCE: Chem. Ber. (1981), 114(7), 2580-94
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB Reaction of oxazolinones I (R = mesityl; R1 = Me2CH, Me2CHCH2, EtMeCH) with R2CH:CHR3 [R2 = H, CN; R3 = CN, COMe, CHO, etc.; R2R3 = (CH2)3CO] in the presence of Et3N resulted in addn. exclusively at C-4 of the oxazoline to give II, which upon hydrolysis with NaOH gave RCONHCR1(CO2H)CHR2CH2R3 (III). Oxidn. of III with Pb(OAc)4 gave R1COCHR2CH2R3.

IT **79137-81-8P 79137-88-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of, with lead tetraacetate)

RN 79137-81-8 CAPLUS
CN L-Leucine, 2-[2-(methylsulfonyl)ethyl]-N-(2,4,6-trimethylbenzoyl)- (9CI) (CA INDEX NAME)



RN 79137-88-5 CAPLUS
CN Butanoic acid, 2-(2-cyanoethyl)-4-(methylsulfonyl)-2-[(2,4,6-trimethylbenzoyl)amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1972:433867 CAPLUS
DOCUMENT NUMBER: 77:33867
TITLE: Bis-.beta.-chloroethyl sulfides. 3. Sulfones of .alpha.-chloro-.beta.-(.beta.-chloroethylthio)- and .beta.-chloro-.alpha.-(.beta.-chloroethylthio)isobutyric acid
AUTHOR(S): Lin'kova, M. G.; Greiciute, D.; Rasteikiene, L.; Knunyants, I. L.
CORPORATE SOURCE: Inst. Elementoorg. Soedin., Moscow, USSR
SOURCE: Izv. Akad. Nauk SSSR, Ser. Khim. (1972), (2), 372-6
CODEN: IASKA6
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB ClCH2CH2SCH2CMeClCO2R [R = H (I) or Me] kept 5 days with 30% H2O2 in AcOH gave the corresponding sulfones. Similar oxidn. of a 15:85 mixt. of I and ClCH2CH2SCMe(CH2Cl)CO2H (II) gave a negligible amt. of the sulfone of II, and yielded instead ClCH2CH2SO2CH2CMeClCO2H. This with Et3N gave CH2:CMeSO2CH2CH2Cl and eventually CH2:CMeSO2CH:CH2. Oxidn. of mixed ClCH2CH2SCH2CMeClCO2Me and ClCH2CH2SCMe(CH2Cl)CO2Me gave a mixt. contg. 75% ClCH2CMe(CO2Me)SO2CH2CH2Cl (III) and 25% ClCH2CH2SO2CH2CMeClCO2Me. The latter and Et3N gave CH2:CHSO2CH:CMeCO2Me while the former gave CH2:CHSO2CMe(CH2Cl)CO2Me. Sapon. of III with MeOH-NaOH gave CO2 and CH2:CMeSO2CH2CH2OMe. Unlike its unstable isomer, ClCH2CH2SO2CH2CMeClCO2H was remarkably stable and treated with SPCl3 gave ClCH2CH2SO2CH2CMeClCOCl,

which was converted into appropriate amides with PhNH2, p-H2NC6H4CO2Me, p-H2N-C6H4CO2Et, and H2NCH(CHMe2)CO2Et0

IT **21849-24-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21849-24-1 CAPLUS

CN Propanoic acid, 2-chloro-3-[(2-chloroethyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1971:488046 CAPLUS
DOCUMENT NUMBER: 75:88046
TITLE: New yperite derivatives
AUTHOR(S): Knunyants, I. L.; Kildisheva, O. V.; Lin'kova, M. G.; Rasteikiene, L.; Greichiute, D.; Vidugiriene, V.; Pranskiene, T.; Stumbreviciute, Z.
CORPORATE SOURCE: Inst. Elementoorg. Soedin., Moscow, USSR
SOURCE: Puti Sin. Izyskaniya Protivoopukholevykh Prep. (1970),
Volume Date 1968, No. 3, 249-56
CODEN: PSIPA4
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Yperite derivs. of the general formulas R1C(COR)ClCHMeS(CH2)2Cl (I) and R2CClHCR1(COR3)S(CH2)2Cl (II) were prepd. I were prepd. by splitting .alpha.-methyl-.alpha.-chloro-.beta.-mercaptopropionic acid .beta.-(thio lactone) with Cl followed by addn. of ethylene to give MeCl(COCl)CCH2S(CH2)2Cl. Substitution of the Cl atom in the COCl group gave I, with R1 = Cl, and R = Cl, OMe, OH, NHPh, NHCH2Ph, NHC6H4CO2Me-p, NHC6H4CO2Et-p, NHCH(CO2Et)CHMe2, and NHCH(CH2Ph)CO2Et. Also prepd. was ClCH2CH2SCH2CMe(CN)Cl. By oxidn of MeClC(CO2H)CH2S(CH2)2Cl, and carrying out similar transformations, a series of MeCCl(COR)CH2SO2(CH2)2Cl was prepd. with R = OH, Cl, OMe, NHPh, NHC6H4CO2Me-p, NHC6H4CO2-Et-p, NHCH(CH2Ph)CO2Et, and NHCH(CO2Et)CHMe2. II were obtained by addn. of .beta.-chloroethylsulfenyl chloride to acrylic, methacrylic, crotonic, cyclohexylacrylic, and cinnamic acids. II prepd. were (R1, R2, and R3 given): Me, H, Cl; Me, H, OMe; Me, H, OH; Me, H, NHPh; Me, H, NHCH2Ph; Me, H, NHC6H4CO2Me-p; Me, H, NHC6H4CO2Et-p; Me, H, NHCH(CO2Et)CHMe2; Me, H, NHCH(CH2Ph)CO2Et; Me, H, NHCH(CO2H)CHMe2; Me, H, NHCH(CO2H)CH2CHMe2; Me, H, NHCH(CH2Ph)CO2H; Me, H, NEt2; H, Me, Cl; H, Me, OH; H, Me, OEt; H, Me, NH2; H, Me, NHPh; H, H, OEt; H, H, NHPh; and Ph, H, NH2. Also prepd. was ClCHMeCH(CN)SCH2CH2Cl. The structures of some I and II were confirmed by NMR spectra. On storage at room temp. most II isomerized into the corresponding I.

IT **21849-24-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 21849-24-1 CAPLUS
CN Propanoic acid, 2-chloro-3-[(2-chloroethyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1970:435757 CAPLUS
DOCUMENT NUMBER: 73:35757
TITLE: Amino acids containing thio ether groups and their derivatives
INVENTOR(S): Shen, Tsung-Ying; Walford, Gordon L.; Dorn, Conrad P., Jr.
PATENT ASSIGNEE(S): Merck and Co., Inc.
SOURCE: Brit., 20 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1191042		19700506		
PRIORITY APPLN. INFO.:			US	19670726
			US	19680510

AB .beta.-Aralkylthio-substituted .alpha.-amino acids and their derivs., useful in the treatment of inflammation, are prepd. by hydrolysis of the corresponding .alpha.-amino nitriles with acids or the corresponding hydantoin compds. with alkali metal hydroxide or strong acids. Reaction of an .alpha.-substituted benzyl mercaptan with the appropriate halo-.alpha.-aminopropionic acid at elevated temp. in a polar solvent gives title compds., also prepd. by the reaction of an .alpha.-substituted benzyl halide with the appropriate cysteine, or by condensing an appropriate triaryl carbinol with a mercapto .alpha.-amino acid in the presence of BF3.Et2O in HOAc at elevated temp. Thus, a mixt. of 40 g 2-[tris(m-fluorophenyl)methyl-thio]butyraldehyde, 11.5 g NH4Cl, 10.4 g NaCN, 70 ml concd. aq. NH3, and 40 ml EtOH satd. with gaseous NH3 is stirred overnight at room temp. to give S-tris(m-fluorophenyl)methyl-.beta.-methyl-DL-cysteine (I). To a stirred mixt. of 6.05 g L-cysteine in 150 ml refluxing liq. NH3, 15.6 g chloro(p-chlorophenyl)diphenylmethane is added portionwise and the mixt. stirred until a clear soln. results to

give S-(p-chlorophenyldiphenylmethyl)-L-cysteine (II), m. 160-2.degree.. To a stirred mixt. of 8.4 g .beta.-bromo-.alpha.-aminopropionic acid in .apprx.150 ml refluxing liq. NH3 is added portionwise 15.5 g mercapto(p-chlorophenyl)diphenylmethane, and the mixt. stirred until a clear soln. results to give II. To a mixt. of 2.95 g p-chlorophenyldiphenylcarbinol in 10 ml HOAc and 1.5 g anhyd. L-cysteine-HCl at 60.degree., 1.4 ml BF3.Et2O is added. The temp. is raised to 80.degree. and the reaction allowed to continue 45 min to give II. S-Methylisothiourea sulfate (27.8 g) is added to a soln. of 26.7 g I in 100 ml H2O contg. 30 ml concd. aq. NH3 and the mixt. stirred 20 hr at room temp. to give I .alpha.-guanidino-.beta.-[S-tris(m-fluorophenyl)methylthio]valeric acid. Several other examples were given. Many other compds. were cited.

IT **27446-94-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 27446-94-2 CAPLUS

CN Cystine, .beta.,.beta.'-diethyl-.alpha.,.alpha.'-bis(p-tolylsulfonyl)-, DL- (8CI) (CA INDEX NAME)



L5 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1969:77500 CAPLUS

DOCUMENT NUMBER: 70:77500

TITLE: Bis(.beta.-chloroethyl) sulfides. I. Derivatives of .alpha.-methyl-.alpha.-chloro-.beta.-(2-chloroethylthio)propionic and .alpha.-methyl-.alpha.-(2-chloroethylthio)-.beta.-chloropropionic acids

AUTHOR(S): Greiciute, D.; Lin'kova, M. G.; Rasteikiene, L.; Knunyants, I. L.

CORPORATE SOURCE: Inst. Elementoorg. Soedin., USSR

SOURCE: Izv. Akad. Nauk SSSR, Ser. Khim. (1968), (12), 2764-72

CODEN: IASKA6

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB ClCH2CH2SCH2CMeClCOCl (I) and PhNH2 in Et2O kept 6 hrs. at -50.degree. gave the anilide, m. 35-7.degree.; benzylamine gave the N-benzylamide, m. 51-3.degree., while Et p-aminobenzoate gave 72% p-EtO2CC6H4NHCOCMe-ClCH2SCH2CH2Cl, m. 60-1.degree.; Me ester analog m. 67-8.degree.. dl-Valine Et ester in a similar reaction in the presence of Et3N in CHCl3 gave 71% EtO2CCH(CHMe2)NHCOCMeClCH2SCH2CH2Cl, m.p. unstated; dl-phenylalanine analog, an oil, was prepd. similarly. ClCH2CH2SCl and

methacrylamides in Et2O or CHCl3 gave the following ClCH2CH2SCMe(CH2Cl)COR (R shown): NHPh, m. 35-7.degree.; NHCH2Ph, m. 54-5.degree.; NEt2, m. 65-7.degree.; p-NHC6H4CO2Me, m. 102-4.degree.; p-NHC6H4CO2Et, m. 81-3.degree.; NHCH(CH2Ph)CO2H, m. 116-18.degree.; NHCH(CHMe2)CO2H, m. 72-3.degree.; and NHCH(CH2CHMe2)CO2H, m. 94-6.degree.. The yields were 51-77%. I and the theoretical amt. H2O in CHCl3 overnight gave 81% ClCH2CH2SCH2CMeClCO2H, m. 58-60.degree., also formed by addn. of ClSCH2CH2Cl to methacrylyl chloride. Oxidn. of the acid with 30% H2O2 in AcOH 10 days gave the sulfone, m. 111-13.degree., while the use of a limited amt. H2O2 overnight in the cold gave the sulfoxide, m. 98-100.degree.. The adduct of ClSCH2CH2Cl and methacrylic acid was oxidized with 30% H2O2 in AcOH to ClCH2CH2SO2CMe(CH2Cl)CO2H, m. 118-21.degree.. N.M.R. spectra of the products are shown.

IT **21849-24-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21849-24-1 CAPLUS

CN Propanoic acid, 2-chloro-3-[(2-chloroethyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



Same as previous.

=> d his

(FILE 'HOME' ENTERED AT 16:59:30 ON 25 MAR 2002)

FILE 'REGISTRY' ENTERED AT 16:59:41 ON 25 MAR 2002
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 0 S L1
L4 97 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:00:39 ON 25 MAR 2002
L5 19 S L4

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.43	229.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.77	-11.77

STN INTERNATIONAL LOGOFF AT 17:09:52 ON 25 MAR 2002

Connection closed by remote host

DOCUMENT NUMBER: 129:244921
TITLE: Preparation of aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds as matrix metalloprotease inhibitors
INVENTOR(S): Freskos, John N.; Boehm, Terri L.; Mischke, Brent V.; Heintz, Robert M.; Mcdonald, Joseph J.; Decrescenzo, Gary A.; Howard, Susan C.
PATENT ASSIGNEE(S): Monsanto Company, USA
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839326	A1	19980911	WO 1998-US4277	19980304
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9864478	A1	19980922	AU 1998-64478	19980304
AU 737329	B2	20010816		
EP 984959	A1	20000315	EP 1998-910177	19980304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9808150	A	20000328	BR 1998-8150	19980304

PRIORITY APPLN. INFO.: US 1997-35182P P 19970304
WO 1998-US4277 W 19980304

OTHER SOURCE(S): MARPAT 129:244921

AB The title compds. HONHC(O)C(OH)(R2)CH2SO2R1 [I; R2 = H, C1-4 alkyl, C1-4 haloalkyl, etc.; R1 = 5-6 membered cycloalkyl, heterocyclyl, aryl, etc.] which inter alia inhibit matrix metalloprotease activity, were prepd. Thus, multi-step synthesis of I [R1 = 4-PhOC6H4; R2 = Me] which showed 51.9% inhibition of angiogenesis in the cornea of a mouse, was described.

IT **213184-20-4P 213184-29-3P 213184-51-1P**
213184-61-3P 213184-63-5P 213184-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. sulfonyl alpha-hydroxy hydroxamic acid compds. as matrix metalloprotease inhibitors)

RN 213184-20-4 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-29-3 CAPLUS
CN Propanoic acid, 3-[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 213184-51-1 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[(4-nitrophenyl)sulfonyl]- (9CI) (CA
INDEX NAME)



RN 213184-61-3 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-63-5 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(3-

methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 213184-65-7 CAPLUS
CN Propanoic acid, 2-hydroxy-2-methyl-3-[[4-[[[(4-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:532307 CAPLUS
DOCUMENT NUMBER: 122:278041
TITLE: Photographic couplers having a ballast containing a sulfone or sulfoxide group
INVENTOR(S): Krishnamurthy, Sundaram; Cowan, Stanley W.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5399467	A	19950321	US 1993-144754	19931029
EP 653676	A1	19950517	EP 1994-203077	19941022
EP 653676	B1	19991229		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07181647	A2	19950721	JP 1994-264772	19941028

PRIORITY APPLN. INFO.: US 1993-144754 19931029
OTHER SOURCE(S): MARPAT 122:278041
AB Novel photog. Ag halide materials contain dye-forming couplers K-NHC(O)C(R2)(-L_R)SOn-R1 [n = 1 or 2; R2 = H, substituent; R and R1 = substituent; L is selected from the group consisting of O, S, Se, Te,

Si(R5)2, NR5, PR5, P(O)(R5)2 and NR5SO2; (R5 = H, alkyl or aryl); and K is a coupler moiety selected from the group consisting of pyrazolone, phenol, and naphthol]. The couplers exhibit increased coupling activity, and provide formation of dyes having improved max. magenta image dye d., contrast, and development speed.

IT **162849-51-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (photog. couplers having ballast contg. sulfone or sulfoxide group)

RN 162849-51-6 CAPLUS

CN Butanoic acid, 2-[(4-methylphenyl)sulfonyl]-2-(3-pentadecylphenoxy)- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:640883 CAPLUS

DOCUMENT NUMBER: 119:240883

TITLE: Metabolism of Casodex in laboratory animals

AUTHOR(S): Boyle, G. W.; McKillop, D.; Phillips, P. J.; Harding, J. R.; Pickford, R.; McCormick, A. D.

CORPORATE SOURCE: Saf. Med. Dep., ICI Pharm., Alderley Park/Macclesfield/Cheshire, SK10 4TG, UK

SOURCE: Xenobiotica (1993), 23(7), 781-98
CODEN: XENOBH; ISSN: 0049-8254

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Casodex, a non-steroidal antiandrogen, was eliminated primarily in feces by rat, mouse, rabbit and dog. Rat, mouse and rabbit eliminated 20-30% of a single oral dose (8-25 mg/kg) in urine; only 3-4% was excreted in urine by dog (2.5 mg/kg). Oral absorption was about 80% in rat, mouse, rabbit and dog. Most of the dose was recovered in 48 h from rat, mouse and rabbit. In rat, <1% of the dose was exhaled as 14CO2 and <1% remained in the carcass after 7 days. Recovery from dog was incomplete in 4 days but consistent with the long plasma elimination half-life of 7-7.5 days. Casodex was eliminated from rat plasma with a half-life of 17-21 h. Examn. of urine indicated extensive metab. of Casodex and showed a marked species difference. In rat, mouse and dog. Casodex was cleaved at the amide to yield a carboxylic acid and an arom. amine which subsequently underwent ring hydroxylation with sulfate conjugation. In rabbit, the major urinary metabolite was Casodex glucuronide, conjugated on the tertiary hydroxyl. The major component in feces of all species was unchanged Casodex; some hydroxy-Casodex was also obsd. in rat feces. Anal. of rat and dog bile indicated that Casodex and hydroxy-Casodex were

eliminated in bile primarily as glucuronide conjugates.

IT **151262-57-6**
RL: FORM (Formation, nonpreparative)
(formation of, as Casodex metabolite, species differences in)

RN 151262-57-6 CAPLUS

CN Propanoic acid, 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:614094 CAPLUS

DOCUMENT NUMBER: 111:214094

TITLE: Chemistry of novel compounds with a multifunctional carbon structure. 5. Molecular design of versatile building blocks for aliphatic monofluoro molecules by manipulation of multifunctional carbon structure

AUTHOR(S): Takeuchi, Yoshio; Nagata, Kazuhiro; Koizumi, Toru

CORPORATE SOURCE: Fac. Pharm. Sci., Toyama Med. Pharm. Univ., Toyama, 930-01, Japan

SOURCE: J. Org. Chem. (1989), 54(23), 5453-9
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:214094

AB Three kinds of doubly functionalized monofluoromethylene fragments, PhSO2CRFNO2 (R = Me, PhCH2, CH2CO2Et, CH2CH2COMe), PhSO2CRFCO2Et (R = PhCH2, CH2CH2COMe) and O2NCRFCO2Et (I, R = PhCH2 CH2CH2CO2Et, CH2CH2COMe, CHPhCH2COMe, CH2CH2CN) potentially versatile building blocks for the general synthesis of various aliph. monofluoro mols., were prepd. from the corresponding difunctional compds. by monoalkylations and selective fluorinations. The interconversion or reductive removal of each functional group followed by the introduction of the second alkyl groups (R') at the fluorine-bearing carbon atom was examd. I proved to be useful and practical building blocks for conversions to the various monofluoroalkanes.

IT **122876-09-9P 122876-10-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 122876-09-9 CAPLUS

CN Benzenepropanoic acid, .alpha.-fluoro-.alpha.-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 122876-10-2 CAPLUS
CN Hexanoic acid, 2-fluoro-5-oxo-2-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:150945 CAPLUS
DOCUMENT NUMBER: 108:150945
TITLE: Amino acid sulfones: S-benzyl-DL-.alpha.-methylcysteine sulfone
AUTHOR(S): Griffith, Owen W.
CORPORATE SOURCE: Med. Coll., Cornell Univ., New York, NY, 10021, USA
SOURCE: Methods Enzymol. (1987), 143(Sulfur Sulfur Amino Acids), 274-9
CODEN: MENZAU; ISSN: 0076-6879
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of S-benzyl-DL-.alpha.-methylcysteine sulfone from S-benzyl-.alpha.-methylcysteine by oxidn. is described. In addn. the reductive cleavage of the sulfone with Na/liq. NH3 to give DL-.alpha.-Me cysteinesulfonic acid is detailed. Also, a general method for the prepn. of S-benzyl derivs. of amino acids contg. thiol or disulfide groups is given.

IT **113737-61-4P**, S-Benzyl-DL-.alpha.-methylcysteine sulfone
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reductive cleavage to sulfinic acid deriv.)
RN 113737-61-4 CAPLUS
CN Alanine, 2-methyl-3-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)